Eli Lilly & Co. has been laying the groundwork for a broader move into women’s health, assembling experts and hunting for new medicines across conditions including bone health and endometriosis, ...

If you look at Eli Lilly's second-quarter revenues, you come away with a very clear picture of the pharmaceutical company's business. Mounjaro, Zepbound, and Foundayo account for nearly two-thirds of ...

Eli Lilly remains on a shopping spree, agreeing to pay up to $2.875 billion in cash for biotechnology company Merida Biosciences in a deal that bolsters the drugmaker’s immunology portfolio. Eli Lilly ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Eli Lilly said Wednesday it is suing six companies selling versions of its experimental weight-loss drug retatrutide, calling it the beginning of a concerted effort to crack down on a vast illicit ...

Eli Lilly is suing six entities that it alleges are selling black market versions of its experimental weight-loss drug retatrutide. Lilly’s lawsuits target U.S. entities selling illegal retatrutide ...

Eli Lilly LLY-0.12%decrease; down pointing triangle has filed six new lawsuits against U.S. entities that it alleges are selling a version of the company’s investigational weight-loss drug on the ...

Eli Lilly, the American drug giant, had another record-breaking quarter. The weight-loss injection Zepbound saw sales soar 46% in the second quarter to $4.9 billion. The FactSet consensus was for $4.7 ...

Mounjaro sales jump 91% driven by international strength Higher-margin sales of blockbuster GLP-1 drugs offset lower prices Lilly narrows 2026 adjusted EPS forecast after deal-related charges Shares ...

Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news like ...

Eli Lilly will expand its partnership with CDMO Resilience. The companies will spend $750 million to upgrade Resilience's injectables manufacturing site near Cincinnati, Ohio. (Photo by Scott ...

Novo Nordisk has sued Eli Lilly over what Novo said is false and misleading advertising comparing the effectiveness of the drug companies' respective injectable weight loss medicines. The lawsuit, ...